Considerations for Estimating Causal Effects of Informatively Timed Treatments
Arman Oganisian · 2025
Read Considerations for Estimating Causal Effects of Informatively Timed Treatments by Arman Oganisian (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/arxiv-2508-21804.txt.
Introduction
Oganisian warns that the timing of care can skew cause-and-effect scores in health studies in this twenty twenty-five paper. In many studies, care picks do not fall on set dates for all patients. The gap between picks can itself hint at what care comes next and how a patient fares.
Inside, the author shows how waits between care picks act as a shifting factor that must be weighed. Worked mock cases show that scores can bend when that wait is left out of the math. Steps that weigh the wait set the score right, even when some patients die mid-course. The paper ends with plain how-to notes and links to free tools for the fix.
Catalog record
| CREATOR | Arman Oganisian |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 56 KB |
| VERSION | 1.0 |
| LICENSE | http://creativecommons.org/licenses/by/4.0/ |
| RIGHTS | CC BY |
| SOURCE | arXiv |
Source: https://arxiv.org/abs/2508-21804
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Considerations for Estimating Causal Effects of Informatively Timed Treatments In press at Epidemiology . Code available at: https://github.com/stablemarkets/informative_timing . Arman Oganisian Abstract Epidemiological studies are often concerned with estimating causal effects of a sequence of treatment decisions on survival outcomes. In many settings, treatment decisions do not occur at fixed, pre-specified followup times. Rather, timing varies across subjects in ways that may be informative of subsequent treatment decisions and potential outcomes. Awareness of the issue and its potential solutions is lacking in the literature, which motivate this work. Here, we formalize the issue of informative timing, problems associated with ignoring it, and show how g-methods can be used to analyze sequential treatments that are informatively timed. As we describe, in such settings, the waiting times between successive treatment decisions may be properly viewed as a time-varying confounders. Using synthetic examples, we illustrate how g-methods that do not adjust for these waiting times may be biased and how adjustment can be done in scenarios where patients may die or be censored in between treatments. We draw connections between adjustment and identification with discrete-time versus continuous-time models. Finally, we provide implementation guidance and examples using publicly available software. Our concluding message is that 1) considering timing is important for valid inference and 2) correcting for informative timing can be done with g-methods that adjust for waiting times between treatments as time-varying confounders. 1 Introduction Epidemiological studies often target the causal effect of a sequence of treatment decisions on an event-time outcome. This is especially common in studies of chronic diseases, which are managed with a series of treatment decisions over time rather than administering a single point-treatment. These decisions are not made at fixed, pre-specified followup times. Rather, the timing varies across subjects in ways that are informative of subsequent treatment decisions and outcomes. G-methods provide valid causal inference for time-varying treatments in the presence of time-varying confounding [ 4 , 19 , 23 , 24 ] . However, it is not obvious how these methods can be used in settings with informative, irregularly timed treatments. The purpose of this manuscript is to 1) illustrate biases due to ignoring timing and 2) describe how g-methods can be implemented to adjust for it. As our central motivating example, will consider recent studies assessing the effects of chemotherapy treatments on survival among patients with pediatric acute myeloid leukemia (AML) [ 21 , 6 , 7 ] . These are secondary analyses of the AAML1031 and AAML1053 trials in which enrolled patients moved through multiple treatment courses. At the start of each course, covariates were measured and used to inform the decision to administer anthracyclene chemotherapy (ACT) or some other non-anthracycline chemotherapy (nACT) at that course. The scientific quantity of interest was the proportion of patients that would have survived at least 3 years under various ACT administration strategies. Note ACT inclusion was not randomized in the trial. Due to cardiotoxicity of ACT, ejection fraction (EF) was monitored at each course. Patients with high EF were more likely to be given ACT. An additional complication is that patients did not and, indeed, could not initiate each course at pre-set, protocol-defined times. This is because chemotherapy is physically taxing and a subsequent course could only be initiated when a subject was deemed sufficiently stable. According to the AAML1031 trial protocol [ 1 ] , “Patients should progress to the next course of therapy as soon as clinically acceptable…Patients should have time for full or partial recovery from any toxicities experienced in the prior course(s).” Subjects recovering faster between courses may be systemically better off and tolerate their initial treatment well. As a result, they may both have better future potential survival and be less likely to change their previous treatment. In this sense, the waiting times between treatments can be considered as a kind of time-varying confounder - which we call “informative timing”. As another example, consider the use of bisphosphonates in patients diagnosed with osteoporosis [ 10 , 9 ] . Bisphosphonates are a class of drugs used to treat osteoporosis. Since long-term use is thought to lead to increased adverse events, it is common to switch patients to a second-line therapy such as teriparatide or denosumab [ 18 ] . We can formalize this as a two-course treatment - a first-line treatment decision followed by a second-line treatment decision. The target of inference is cumulative risk of hip fracture or atypical femoral fracture. As in the AML example, different patients switch after different durations of bisphosphonate therapy. The length of time on first-line therapy may be informative of which drug they switch to as well as outcomes. Using AAML1031 as a motivator, we begin by formalizing the problem of informative timing as a type of time-varying confounding. Then, we describe continuous-time approaches for adjusting for informative timing via inverse-probability of treatment weighting (IPTW). Continuous-time causal approaches have been used for structural nested modeling [ 17 ] , structural nested failure time modeling [ 16 ] , and marginal structural modeling [ 25 , 26 ] . In epidemiological research, discrete-time causal models are also common and some work has investigated the impact of discretizing continuous data [ 30 , 5 , 27 ] . We build on this literature in Section 5 by providing an equivalent discrete-time framing and adjustment for the issue of informative timing. 2 Potential Outcomes and Informative Timing Consider a case with K treatment courses indexed by k=1,2,\dots,K . For simplicity of exposition, we consider a case with just K=2 courses each of which have two possible treatment options which we denote as A_{k}\in\{0,1\} , respectively. For example, patients undergo K=2 courses of chemotherapy and at each course there are two possible chemotherapy agents, ACT ( A_{k}=1 ) or nACT ( A_{k}=0 ). Following the template of the AAML1031 trial, start of followup (time-zero) is the time of the first ( k=1 ) treatment course for each patient. Let L_{k} denote the set of confounders measured at course k just before the treatment decision A_{k} . For concreteness, this could include EF in the AAML1031 context. At course k=1 , L_{1} is measured and used to inform ACT assignment, A_{1} . After this course, patients take some time to recover and initiate their second course W_{1} time units later. If they reach course k=2 , confounders L_{2} are once again measured and, along with available information (A_{1},L_{1},W_{1}) , is used to inform ACT decision A_{2} . After the initiation of the second treatment course, there is some waiting time W_{2} until death, measured in units of time since start of course k=2 . Of interest is a survival time outcome, T>0 . For a subject who survived through two treatment courses, the survival time is the sum of the waiting times T=W_{1}+W_{2} . This process is illustrated in the the directed acyclic graph (DAG) in Figure 1(a) . The backdoor path A_{2}\leftarrow W_{1}\rightarrow W_{2} is what we refer to as “informative timing.” That is, two patients who received A_{2}=1 vs. A_{2}=0 in their second treatment course at different times W_{1} are, in general, not exchangeable with respect to subsequent survival time W_{2} - even if the match exactly on A_{1}